HARPREET BAL: Open Payments
NPI 1760035976 · OAKLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 51 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $319 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $343 |
| Neurocrine BioSciences, Inc. | 11 | $298 |
| PFIZER INC. | 6 | $134 |
| Teva Pharmaceuticals USA, Inc. | 3 | $117 |
| Axsome Therapeutics, Inc. | 3 | $85 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| Lilly USA, LLC | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Lundbeck LLC | 1 | $32 |
| Octapharma USA, Inc. | 1 | $28 |
Products named: INGREZZA, QULIPTA, NURTEC ODT, UBRELVY, Symbravo, BOTOX, AUSTEDO XR, KISUNLA.
Industry payments across CA — which companies pay providers there.
